Write in a clean editor, then format for Expert Review of Anticancer Therapy in one click — DocuGuru applies the official Taylor & Francis template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Expert Review of Anticancer Therapy is a peer-reviewed journal published by Taylor & Francis, covering Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments.
| Publisher | Taylor & Francis |
|---|---|
| Reference style | Numbered (Vancouver/NLM) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. Expert Review of Anticancer Therapy. 2023;12(3):45–58.
Formats any DOI in Expert Review of Anticancer Therapy style. No sign-up. |
| Publishes research in | Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Bladder and Urothelial Cancer Treatments Renal cell carcinoma treatment Cancer Genomics and Diagnostics |
| ISSN | 1473-7140 |
| Citation impact (2-yr) | 2.57 |
| h-index | 98 |
| i10-index | 1,945 |
| Total citations | 74,439 |
| Top institutions publishing here | The University of Texas MD Anderson Cancer Center |
| Journal website | informahealthcare.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
INTRODUCTION: Current treatment of osteosarcoma includes surgical resection of all gross disease in conjunction with systemic chemotherapy to control micro-metastatic disease. This yields a 5-year event free survival (EFS) of approximately 70% for patients with localized osteosarcoma while patients with metastatic or recurrent disease fare poorly with overall survival rates of less than 20%. Areas…
INTRODUCTION: The eighth edition of the American Joint Committee on Cancer (AJCC) melanoma staging system was implemented in the United States on 1 January 2018. Areas covered: This article provides an overview of important changes in the eighth edition AJCC staging system from the seventh edition based on analyses of a large international melanoma database.…
HER2 amplification is seen in up to 20% of breast cancers and is associated with an aggressive phenotype. Trastuzumab, a monoclonal antibody to HER2, accrues significant clinical benefit in the metastatic and adjuvant settings. However, some patients suffer disease recurrence despite adjuvant trastuzumab therapy, and many patients with metastatic disease do not respond to therapy…
INTRODUCTION: Children with neuroblastoma have widely divergent outcomes, ranging from cure in >90% of patients with low risk disease to <50% for those with high risk disease. Recent research has shed light on the biology of neuroblastoma, allowing for more accurate risk stratification and treatment reduction in many cases, although newer treatment strategies for children…
For patients with osteosarcoma, the use of chemotherapy has improved survival from 11% with surgical resection alone in the 1960s, to 70% by the mid-1980s. However, survival has since plateaued, despite advances in anticancer therapy. Elucidation of the mechanisms of chemoresistance and implementation of strategies to overcome chemoresistance will likely be pivotal to improving survival.…
